It's no secret that during the COVID-19 pandemic, the global life sciences industry shined. It ramped up development of everything from diagnostic tests to new vaccines — including two based on previously unproven messenger RNA technology —all within months instead of years.
At the Bio International Convention this week at the San Diego Convention Center, the industry took stock of those accomplishments, as well as asked what's next now that the pandemic has entered an endemic phase.
Can messenger RNA — the technology underpinning vaccines from Moderna and Pfizer-BioNTech — be made durable and effective enough to treat other diseases beyond COVID?
